Cancer CD Antigen Inhibitors Market Sales Revenue Clinical Trials Pipeline Report 2015

Pharmaceutical companies are continuously looking for better therapeutic options to effectively cure and prevent various malignancies. Several options for cancer treatment are available belonging to various classes of molecules. Different types of cancer have different pathophysiological characteristics due to which distinctive approach is required for effective treatment. Several molecules have been discovered out of which CD antigens have been found to play an important role in cancer progression and proliferation. Investigators are trying to assign different functions to CD antigens by doing extensive research and development. Their role in cancer development has been noted due to which lots of progress would be observed in this segment. Most of the work has been done in cancer segment and pharmacological profiles are expected to be improved in coming years.

Download Report:

https://www.kuickresearch.com/report-Cancer-CD-Antigen-Inhibitors-Market-&-Pipeline-Insight2015.php

For Report Sample Contact: neeraj@kuickresearch.com or +91-11-47067990

"Cancer CD Antigen Inhibitors Market & Pipeline Insight 2015"
Table of Contents

1. Introduction to CD Antigens

2. Nomenclature & Classification of CD Antigens

3. Mechanism of CD Antigen Cancer Therapeutics

4. Cancer CD Antigen Therapy Market Overview
4.1 Current Scenario
4.2 Cancer CD Antigen Inhibitors Pipeline Overview

5. CD Antigen Cancer Market Dynamics
5.1 Favorable Market Parameters
5.2 Commercialization Challenges

6. CD Antigen Cancer Therapeutics Future Prospects

7. Cancer CD Antigen Inhibitors Clinical Pipeline by Company, Indication & Phase
7.1 Phase-I/II

8. Cancer CD3 Antigen Inhibitors Clinical Pipeline by Company, Indication & Phase
8.1 Preclinical till Phase-II

9. Cancer CD4 Antigen Inhibitors Clinical Pipeline by Company, Indication & Phase
9.1 Phase-II

10. Cancer CD9 Antigen Inhibitors Clinical Pipeline by Company, Indication & Phase
10.1 Preclinical

11. Cancer CD11 Antigen Inhibitors Clinical Pipeline by Company, Indication & Phase
11.1 Preclinical

12. Cancer CD19 Antigen Inhibitors Clinical Pipeline by Company, Indication & Phase
12.1 Phase-I till Phase-II

13. Cancer CD20 Antigen Inhibitors Clinical Pipeline by Company, Indication & Phase
13.1 Research till Phase-III
13.2 Marketed CD20 Antigen Inhibitors Drug Clinical Insight

14. Cancer CD22 Antigen Inhibitors Clinical Pipeline by Company, Indication & Phase
14.1 Phase-II till Phase-III

15. Cancer CD26 Antigen Inhibitors Clinical Pipeline by Company, Indication & Phase
15.1 Preclinical till Phase-I/II

16. Cancer CD27 Antigen Inhibitors Clinical Pipeline by Company, Indication & Phase
16.1 Research till Phase-I/II

17. Cancer CD28 Antigen Inhibitors Clinical Pipeline by Company, Indication & Phase
17.1 Preclinical

18. Cancer CD29 Antigen Inhibitors Clinical Pipeline by Company, Indication & Phase
18.1 Preclinical

19. Cancer CD33 Antigen Inhibitors Clinical Pipeline by Company, Indication & Phase
19.1 Phase-I till Phase-I/II
19.2 Marketed CD33 Antigen Inhibitors Drug Clinical Insight

20. Cancer CD37 Antigen Inhibitors Clinical Pipeline by Company, Indication & Phase
20.1 Phase-I till Phase-II

21. Cancer CD38 Antigen Inhibitors Clinical Pipeline by Company, Indication & Phase
21.1 Research till Preregistration

22. Cancer CD40 Antigen Inhibitors Clinical Pipeline by Company, Indication & Phase
22.1 Phase-I

23. Cancer CD44 Antigen Inhibitors Clinical Pipeline by Company, Indication & Phase
23.1 Preclinical

24. Cancer CD45 Antigen Inhibitors Clinical Pipeline by Company, Indication & Phase
24.1 Preclinical till Phase-II

25. Cancer CD47 Antigen Inhibitors Clinical Pipeline by Company, Indication & Phase
25.1 Preclinical till Phase-I

26. Cancer CD52 Antigen Inhibitors Clinical Pipeline by Company, Indication & Phase
26.1 Research till Preclinical
26.2 Marketed CD52 Antigen Inhibitors Drug Clinical Insight

27. Cancer CD55 Antigen Inhibitors Clinical Pipeline by Company, Indication & Phase
27.1 Preclinical till Phase-II

28. Cancer CD56 Antigen Inhibitors Clinical Pipeline by Company, Indication & Phase
28.1 Preclinical till Phase-II

29. Cancer CD66 Antigen Inhibitors Clinical Pipeline by Company, Indication & Phase
29.1 Preclinical till Phase-II

30. Cancer CD70 Antigen Inhibitors Clinical Pipeline by Company, Indication & Phase
30.1 Phase-I

31. Cancer CD74 Antigen Inhibitors Clinical Pipeline by Company, Indication & Phase
31.1 Preclinical till Phase-I/II

32. Cancer CD80 Antigen Inhibitors Clinical Pipeline by Company, Indication & Phase
32.1 Preclinical till Phase-II

33. Cancer CD95 Antigen Inhibitors Clinical Pipeline by Company, Indication & Phase
33.1 Preclinical

34. Cancer CD98 Antigen Inhibitors Clinical Pipeline by Company, Indication & Phase
34.1 Phase-I

35. Cancer CD100 Antigen Inhibitors Clinical Pipeline by Company, Indication & Phase
35.1 Phase-I

36. Cancer CD117 Antigen Inhibitors Clinical Pipeline by Company, Indication & Phase
36.1 Preclinical till Phase-III
36.2 Marketed CD117 Antigen Inhibitors Drug Clinical Insight

37. Cancer CD135 Antigen Inhibitors Clinical Pipeline by Company, Indication & Phase
37.1 Preclinical till Phase-III
37.2 Marketed CD135 Antigen Inhibitors Drug Clinical Insight

38. Cancer CD137 Antigen Inhibitors Clinical Pipeline by Company, Indication & Phase
38.1 Preclinical

39. Cancer CD152 Antigen Inhibitors Clinical Pipeline by Company, Indication & Phase
39.1 Marketed CD152 Antigen Inhibitors Drug Clinical Insight

40. Cancer CD200 Antigen Inhibitors Clinical Pipeline by Company, Indication & Phase
40.1 Preclinical

41. Cancer CD223 Antigen Inhibitors Clinical Pipeline by Company, Indication & Phase
41.1 Research till Phase-I

42. Cancer CD227 Antigen Inhibitors Clinical Pipeline by Company, Indication & Phase
42.1 Phase-I till Phase-II

43. Cancer CD246 Antigen Inhibitors Clinical Pipeline by Company, Indication & Phase
43.1 Preclinical till Phase-II
43.2 Marketed CD246 Antigen Inhibitors Drug Clinical Insight

44. Cancer CD248 Antigen Inhibitors Clinical Pipeline by Company, Indication & Phase
44.1 Phase-II

45. Cancer CD274 Antigen Inhibitors Clinical Pipeline by Company, Indication & Phase
45.1 Research till Phase-III
45.2 Marketed CD274 Antigen Inhibitors Drug Clinical Insight

46. Cancer CD276 Antigen Inhibitors Clinical Pipeline by Company, Indication & Phase
46.1 Phase-I

47. Cancer CD279 Antigen Inhibitors Clinical Pipeline by Company, Indication & Phase
47.1 Phase-I till Phase-II
47.2 Marketed CD279 Antigen Inhibitors Drug Clinical Insight

48. Multiple Cancer CD Antigen Inhibitors Clinical Pipeline by Company, Indication & Phase
48.1 Preclinical till Phase-III
48.2 Marketed Multiple CD Antigen Inhibitors Drug Clinical Insight

49. Discontinued & Suspended Cancer CD Antigen Inhibitors Drug Clinical Insight
49.1 No Development Reported
49.2 Discontinued
49.3 Market Withdrawal
49.4 Suspended

50. Competitive Landscape
50.1 Alexion Pharmaceuticals
50.2 ARIAD Pharmaceuticals
50.3 AryoGen Biopharma
50.4 AXXO
50.5 Bayer HealthCare
50.6 Biocad
50.7 Biogen
50.8 Biotecnol Inc.
50.9 Bristol-Myers Squibb
50.10 Chugai Pharmaceutical
50.11 Dr Reddy’s Laboratories
50.12 Eisai Co Ltd
50.13 Emergent BioSolutions
50.14 Genmab
50.15 ImmunoGen
50.16 Intas Biopharmaceuticals
50.17 MacroGenics
50.18 MedImmune
50.19 Merck
50.20 Novartis
50.21 Ono Pharmaceutical
50.22 Onyx Pharmaceuticals
50.23 Pfizer
50.24 PROBIOMED
50.25 Roche
50.26 UCB
50.27 Xencor

Figure 1-1: Functions of CD Antigens
Figure 1-2: Properties of CD Antigens
Figure 2-1: Types of WBC
Figure 2-2: Classification of CD Antigens
Figure 3-1: Important Features of CD Antigens
Figure 3-2: Mechanism of Rituximab
Figure 3-3: Mechanism of Brentuximab Vedotin
Figure 3-4: Mechanism of Blinatumomab
Figure 3-5: Mechanism of Ibritumomab Tiuxetan
Figure 3-6: Mechanism of Tositumomab Iodine 131
Figure 3-7: Mechanism of Catumaxomab
Figure 4-1: Cancer CD Antigen Inhibitors Pipeline by Phase (%), 2015
Figure 4-2: Cancer CD Antigen Inhibitors Pipeline by Phase (Number), 2015
Figure 4-3: Cancer CD3 Antigen Pipeline by Phase (%), 2015
Figure 4-4: Cancer CD3 Antigen Pipeline by Phase (Number), 2015
Figure 4-5: Cancer CD19 Antigen Pipeline by Phase (%), 2015
Figure 4-6: Cancer CD19 Antigen Pipeline by Phase (Number), 2015
Figure 4-7: Cancer CD20 Antigen Pipeline by Phase (%), 2015
Figure 4-8: Cancer CD20 Antigen Pipeline by Phase (Number), 2015
Figure 4-9: Cancer CD22 Antigen Pipeline by Phase (%), 2015
Figure 4-10: Cancer CD22 Antigen Pipeline by Phase (Number), 2015
Figure 4-11: Cancer CD26 Antigen Pipeline by Phase (%), 2015
Figure 4-12: Cancer CD26 Antigen Pipeline by Phase (Number), 2015
Figure 4-13: Cancer CD27 Antigen Pipeline by Phase (%), 2015
Figure 4-14: Cancer CD27 Antigen Pipeline by Phase (Number), 2015
Figure 4-15: Cancer CD33 Antigen Pipeline by Phase (%), 2015
Figure 4-16: Cancer CD33 Antigen Pipeline by Phase (Number), 2015
Figure 4-17: Cancer CD38 Antigen Pipeline by Phase (%), 2015
Figure 4-18: Cancer CD38 Antigen Pipeline by Phase (Number), 2015
Figure 4-19: Cancer CD45 Antigen Pipeline by Phase (%), 2015
Figure 4-20: Cancer CD45 Antigen Pipeline by Phase (Number), 2015
Figure 4-21: Cancer CD47 Antigen Pipeline by Phase (%), 2015
Figure 4-22: Cancer CD47 Antigen Pipeline by Phase (Number), 2015
Figure 4-23: Cancer CD52 Antigen Pipeline by Phase (%), 2015
Figure 4-24: Cancer CD52 Antigen Pipeline by Phase (Number), 2015
Figure 4-25: Cancer CD55 Antigen Pipeline by Phase (%), 2015
Figure 4-26: Cancer CD55 Antigen Pipeline by Phase (Number), 2015
Figure 4-27: Cancer CD56 Antigen Pipeline by Phase (%), 2015
Figure 4-28: Cancer CD56 Antigen Pipeline by Phase (Number), 2015
Figure 4-29: Cancer CD66 Antigen Pipeline by Phase (%), 2015
Figure 4-30: Cancer CD66 Antigen Pipeline by Phase (Number), 2015
Figure 4-31: Cancer CD74 Antigen Pipeline by Phase (%), 2015
Figure 4-32: Cancer CD74 Antigen Pipeline by Phase (Number), 2015
Figure 4-33: Cancer CD80 Antigen Pipeline by Phase (%), 2015
Figure 4-34: Cancer CD80 Antigen Pipeline by Phase (Number), 2015
Figure 4-35: Cancer CD117 Antigen Pipeline by Phase (%), 2015
Figure 4-36: Cancer CD117 Antigen Pipeline by Phase (Number), 2015
Figure 4-37: Cancer CD135 Antigen Pipeline by Phase (%), 2015
Figure 4-38: Cancer CD135 Antigen Pipeline by Phase (Number), 2015
Figure 4-39: Cancer CD223 Antigen Pipeline by Phase (%), 2015
Figure 4-40: Cancer CD223 Antigen Pipeline by Phase (Number), 2015
Figure 4-41: Cancer CD227 Antigen Pipeline by Phase (%), 2015
Figure 4-42: Cancer CD227 Antigen Pipeline by Phase (Number), 2015
Figure 4-43: Cancer CD246 Antigen Pipeline by Phase (%), 2015
Figure 4-44: Cancer CD246 Antigen Pipeline by Phase (Number), 2015
Figure 4-45: Multiple Cancer CD Antigen Pipeline by Phase (%), 2015
Figure 4-46: Multiple Cancer CD Antigen Pipeline by Phase (Number), 2015
Figure 4-47: Cancer CD Antigen Inhibitors No Development Reported Pipeline by Phase (%), 2015
Figure 4-48: Cancer CD Antigen Inhibitors No Development Reported Pipeline by Phase (Number), 2015
Figure 4-49: Cancer CD Antigen Inhibitors Discontinued Pipeline by Phase (%), 2015
Figure 4-50: Cancer CD Antigen Inhibitors Discontinued Pipeline by Phase (Number), 2015
Figure 4-51: Cancer CD Antigen Inhibitors Suspended Pipeline by Phase (%), 2015
Figure 4-52: Cancer CD Antigen Inhibitors Suspended Pipeline by Phase (Number), 2015
Figure 5-1: Favorable Market Features
Figure 5-2: Cancer CD Antigen Inhibitors Commercialization Challenges

List of Tables
Table 5-1: Different CD Antigens used for Hematological Malignancies

Kuick Research is a market research and analytics company that provides targeted information for critical decisions at business, product and service levels. We are quick, predictive and known by the recommendations we have made in the past. Our result-oriented research methodology offers understanding of multiple issues in a short period of time and gives us the capability to keep you full with loads of practical ideas. By translating research answers into strategic insight and direction, we not only rate the success potential of your products and/or services, but also help you identify the opportunities for growth in new demographies and find ways to beat competition.

Neeraj Chawla
neeraj@kuickresearch.com
KuicK Research
Avanta Business Center 4th Floor,
Statesman House Barakhamba Road,
Connaught Place New Delhi – 110 001, India
+91-11-47067990

This release was published on openPR.